Evaluation of a series of 3, 4-dihydro-2H-l-benzopyran-2-carboxylic acids linked to the 2- hydroxyacetophenone pharmacophore present in the standard peptidoleukotriene antagonist FPL 55712 (1) has led to the discovery of Ro 23-3544 (7), an antagonist possessing greater potency and duration of action vs LTD4 than the standard (aerosol route of administration, guinea pig bronchoconstriction model). Interestingly, this compound ...
![methyl (R,S)-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-1-benzopyran-2-carboxylate Structure](https://image.chemsrc.com/caspic/142/120329-95-5.png)